Bristol-Myers Squibb completed the acquisition of MyoKardia for $13.1bn.

Bristol-Myers Squibb, a global biopharmaceutical company, completed the acquisition of MyoKardia, a clinical-stage biopharmaceutical company discovering and developing targeted therapies for the treatment of serious cardiovascular diseases, for $13.1bn. “We are further strengthening our outstanding cardiovascular franchise through the addition of mavacamten, a promising medicine with the potential to address a significant unmet medical need in patients with cardiovascular disease. Our companies share a commitment to innovation and bold science, and our respective strengths will help us realize the value inherent in this portfolio. We have long admired MyoKardia and what they have done to revolutionize cardiovascular treatments through a precision medicine approach. We look forward to welcoming their talented team to our company," Giovanni Caforio, Bristol Myers Squibb, M.D., Board Chair and CEO.